Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hallux Terbinafine Subungual Gel for Onychomycosis
NCT05135910Phase 2Unknown
- Sponsor
- Hallux Inc.
- Start
- Jan 2022
- Primary completion
- Sep 2024
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Terbinafine subungual gel in onychomycosis, sponsored by Hallux Inc. Primary endpoint: Complete Cure in the Target Toe at Week 52. Status: unknown.
02
Drugs
Terbinafine subungual gel
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT05135910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135910.